Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year.
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
– Strong execution delivered second quarter 2023 total revenues of $957 million – – Commercial excellence drove continued adoption of low-sodium Xywav®; net.